Immune checkpoint inhibitors (ICIs) represent another significant cluster in this field, encompassing a range of molecules, including PD-1, PD-L1, and CTLA-4, which exert anti-tumor effects by regulating the interaction of Treg cells with antigen-presenting cells or tumor cells (85). The gene discussed is CTLA4; the disease is neoplasm.